Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vernakalant in recent onset symptomatic atrial fibrillation
NCT00989001Phase 3Terminated
- Sponsor
- ADVANZ PHARMA
- Start
- Oct 2009
- Primary completion
- Nov 2010
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Vernakalant with Placebo (2 arms). Primary endpoints: Number of Participants who Experience Hypotension, Ventricular Arrhythmias and/or Death at 2 hours and Number of Participant with Successful Conversion to Sinus rhythm (SR) at 90 minutes. Started Oct 2009; status: terminated.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00989001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00989001.